Confluence Advisors, LLC (“Confluence”) served as the exclusive advisor to Cobra Investments Management Inc. and its two subsidiaries, Copperhead Chemical Company Inc., and Copperhead Investments Inc. (collectively “Copperhead”) with respect to its sale to PMC Group International, Inc. (“PMC”).

Located in Tamaqua, Pennsylvania, Copperhead is an FDA registered and current good manufacturing practices (“cGMP”) compliant manufacturer of active pharmaceutical ingredients (“APIs”) and specialty chemical intermediate products.

Copperhead has been the sole manufacturer of the FDA approved cardiac therapeutic drug nitroglycerin in the U.S. for over 70 years and a custom manufacturer of drug dosage forms. It is also a major producer of energetic chemicals (explosives and propellants) for the defense industry as well as a novel class of preservatives and antimicrobials. Copperhead’s products are sold globally.

Cathy McPhail, President and Chief Executive Officer, shared, “The Confluence team was instrumental in closing this transaction, and they were a pleasure to work with from start to finish. They skillfully navigated numerous twists and turns along the way, and their perseverance led us to the desired outcome - getting the deal done.”

About Confluence Advisors, LLC

Confluence Advisors helps business owners maximize the sale of a business, raise optimal funding, or acquire a business. With over 80 years of combined deal experience and more than $2 billion in transactions, the Confluence team works every day to help companies and their stakeholders through critical business transitions.